Japan's FY 2008 health care budget raised 3% to $221B, with disease management up 102%

21 January 2008

The fiscal year 2008 budget for the Japanese Ministry of Health, Labor and Welfare has been increased 3.0% to 22,122.0 billion yen ($221.04 billion), including some 8,564.0 billion yen for the operating costs of health insurance programs (a 1.6% rise on the previous year).

In the disease management budget, 203.7 billion yen, was allocated, a 102% increase. Within this, 20.7 billion yen, 276% more than the previous year, was earmarked for hepatitis countermeasures including the promotion of interferon treatment (12.9 billion yen) and the promotion of hepatitis virus tests (5.1 billion yen).

For cancer prevention, 23.6 billion yen, a 111% rise, was proposed. This includes the prevention and early detection of cancer and the standardization of oncology treatment facilities throughout the nation (8.3 billion yen) and the promotion of radiation therapy and chemotherapy, as well as the fostering of cancer experts (5.4 billion yen). For the infectious diseases - including new types of influenza, 15.1 billion yen was earmarked. In addition, 111.9 billion yen was allocated for intractable disease countermeasures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight